Allarity Therapeutics received a Wells Notice from the SEC on July 19, 2024, concerning its previously disclosed SEC investigation. The notice relates to the company's disclosures about FDA meetings regarding its NDA for Dovitinib or Dovitinib-DRP submitted in 2021. Three former officers also received Wells Notices for the same conduct, which occurred during or prior to fiscal year 2022.The Wells Notice indicates SEC staff's preliminary determination to recommend enforcement action against the company for alleged federal securities law violations. While a Wells Notice does not constitute a formal charge or final determination of law violation, the company maintains its actions were appropriate and plans to submit a formal response while continuing to cooperate with the SEC.

Allarity Therapeutics received a Wells Notice from the SEC on July 19, 2024, concerning its previously disclosed SEC investigation. The notice relates to the company's disclosures about FDA meetings regarding its NDA for Dovitinib or Dovitinib-DRP submitted in 2021. Three former officers also received Wells Notices for the same conduct, which occurred during or prior to fiscal year 2022.The Wells Notice indicates SEC staff's preliminary determination to recommend enforcement action against the company for alleged federal securities law violations. While a Wells Notice does not constitute a formal charge or final determination of law violation, the company maintains its actions were appropriate and plans to submit a formal response while continuing to cooperate with the SEC.